Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Moderna

Biotech Investors: Should You Buy, Hold, or Sell Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR)?

Despite facing several challenges, the biotech sector thrives due to growing demand for effective treatments, consistent innovations, and a sustained demand for high-quality drugs and therapies. Let's assess whether one should Buy, Hold, or Sell biotech stocks Moderna (MRNA) and Arrowhead Pharmaceuticals (ARWR). Keep reading.

StockNews.com · Mar 15, 2024

Covid vaccines cut risk of virus-related heart failure and blood clots, study finds

Researchers say jabs substantially reduce for up to a year the chances of serious cardiovascular complications

The Guardian - UK · Mar 12, 2024

Stocks Close Mildly Lower on Caution Ahead of Tuesday’s U.S. CPI Report

The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.11%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.12%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed -0.37%. Stocks Monday traded mildly lower on a +2.3 bp rise in the 10-year T-note...

Barchart · Mar 11, 2024

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna (MRNA) Earnings Analysis: Buy or Watch for Gains?

Moderna’s (MRNA) mRNA platform is positioned to deliver significant long-term impact with its mRNA medicines, but declining sales amid plummeting demand for its COVID-19 vaccine, steep losses, and cash burn reflect uncertainty around its near-term prospects. As MRNA is set to release its fourth-quarter 2023 results this Thursday, let’s find…

StockNews.com · Feb 20, 2024

Moderna (MRNA) and Biogen (BIIB) - Are There Upsides Left in These Biotech Stocks?

Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).

StockNews.com · Feb 13, 2024

New mRNA 'cancer vaccine' trial launches in UK

The first U.K. patient has received a dose of "cancer vaccine" in a new trial.

LiveScience · Feb 8, 2024

Moderna (MRNA) vs. Exelixis (EXEL) - Which Biotech Stock Is Worth Buying?

The biotech industry is poised for long-term growth, supported by the advancements in personalized medicine and integration with information technology. While leading biotech stocks Moderna (MRNA) and Exelixis (EXEL) should benefit from the industry tailwinds, let us predict which stock is worth buying.

StockNews.com · Jan 19, 2024

Read news from The Economist, FT, and more,
with one subscription

‘Medicine is going personalised’: Moderna’s UK boss on the coming vaccine revolution

Darius Hughes was a key figure in Pfizer’s pioneering Covid vaccine drive. Now he has changed companies – and sees a big future for mRNA technology

The Guardian - UK · Jan 16, 2024

A Biochemist Reveals The One Tech That Could Revolutionize Drug Discovery

How mRNA-based drugs interact with the immune system and how they are degraded in human cells can help lead to safe, durable, and effective treatments.

Inverse · Jan 9, 2024

Moderna's COVID Vaccine Sales Exceed Expectations in 2023!

In a stunning achievement, Moderna recently announced that their preliminary COVID vaccine sales for 2023 have met their target. This is fantastic news for...

Florida Surgeon General's Claims on COVID Vaccines Debunked as Nonsense

Explore the debunked claims made by the Florida State Surgeon General regarding COVID vaccines and the integration of contaminants into DNA in this insight...

Drugs of the future will be easier and faster to make, thanks to mRNA – after researchers work out a few remaining kinks

Vaccines have been reliably and affordably protecting people from diseases worldwide for centuries. Until the COVID-19 pandemic, however, vaccine development was still a long and idiosyncratic process. Traditionally, researchers had to tailor manufacturing processes and facilities for each vaccine candidate, and the scientific knowledge gained from one vaccine was often…

The Conversation · Jan 4, 2024

Covid jabs could be sold on the high street like flu vaccine

Boots and Superdrug have confirmed they are looking at ways to sell Covid vaccines from their high street stores

The Independent UK · Dec 30, 2023

FDA Spots Control Irregularities in Moderna's US Plant

Dive into the intriguing saga of unanticipated control failures at Moderna's magnate production plant, a juicy scoop exclusively unraveled by the meticulou...

Moderna CEO Says Melanoma Vaccine Could Be Available By 2025

Globally there were an estimated 325,000 new melanoma cases and 57 ,000 deaths from the disease in 2020.

Moderna Tests Promising Personalized Skin Cancer Vaccine with 49% Improvement!

Moderna tests a novel approach to battle skin cancer, with a vaccine showing benefits for melanoma patients. Treatment could be available by 2025.

Barchart · Dec 14, 2023

Stocks and Bonds Continue Higher on Dovish Fed and Improved Soft-Landing Prospects

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.41%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.29%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.17%. Stocks this morning are mildly higher, with the S&P...

International Business Times · Dec 14, 2023

Moderna CEO Says Melanoma Vaccine Could Be Available By 2025

Moderna CEO Stephane Bancel told AFP his company's experimental vaccine against melanoma could be available in as little as two years, in what would amount to a landmark step against the most serious form of skin cancer.

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation · Dec 12, 2023

Customizing mRNA is easy, and that's what makes it the next frontier for personalized medicine − a molecular biologist explains

While using mRNA as medicine is new, mRNA has been inside you for your entire life. The cells in your body create mRNAs that serve as instructions to make specific proteins you need to function. Researchers can create new mRNAs to correct those instructions when they aren’t working.

Kiplinger · Nov 23, 2023

Should You Invest In IPOs? It's Still A Risky Prospect

Investing in IPOs may sound exciting, but it's often better to wait for newly public stocks to mature before buying.

The Conversation · Nov 20, 2023

What are the new COVID booster vaccines? Can I get one? Do they work? Are they safe?

As the COVID virus continues to evolve, so does our vaccine response. From December 11, Australians will have access to new vaccines that offer better protection.

Fortune · Nov 3, 2023

Moderna’s CFO on the $25 billion innovation plan to work past the post-COVID slump

“There’s a true organic growth opportunity here,” Jamey Mock says.

Barchart · Oct 18, 2023

Why is Covid-19 Still Affecting the Healthcare Industry?

Back in May, the World Health Organization declared an end to the global Public Health Emergency for Covid-19. Despite the end of the pandemic, however, the healthcare industry is still feeling its effects. Vaccine makers and pharmacy chains are seeing a steep decline in the number of people getting Covid...

The Conversation · Oct 18, 2023

Beyond COVID vaccines: what else could mRNA technology do for our health?

Many people first became familiar with the term “mRNA” when Pfizer’s and Moderna’s COVID vaccines were rolled out. In the simplest terms, mRNA, which stands for messenger ribonucleic acid, is a type of genetic material that gives cells in our bodies instructions to make specific proteins.

Salon · Oct 5, 2023

Flu-COVID combo vaccines on the horizon

Moderna announces plans to move a novel vaccine design into its final stage of development

1 … 11 12 13 14

Coverage From

People

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

World Health Organization

Dow Jones Industrials

US Food and Drug Administration

146 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.